• Cancel
    Date：2021-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=822

    Shanghai Cell Therapy Group, a leading player in the cell therapy industry in China, has announced the successful closing of its Series D1 financing, raising nearly RMB 500 million. The round was jointly invested by Jiuzhou Venture, Sun Rock Capital, and

  • Cancel
    Date：2021-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=823

    Thousand Oaks, a rapidly growing Contract Development and Manufacturing Organization (CDMO) and cell culture biotechnology company, announced today that it has raised over RMB 400 million in its Series C Financing in March 2021. This round of financing wa

  • Cancel
    Date：2021-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=824

    Arctic Vision, a clinical-stage biotech company focused on innovative ophthalmology therapies, announced today that it has successfully raised over $100 million in B round financing. The financing was led by Loyal Valley Capital, with participation from T

  • Cancel
    Date：2021-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=825

    Gensciences Group announced the closing of over RMB 800 million in Series A and B financings. The B round financing was led by HT Capital, with participation from Efung Capital and Huarong Rongde. Existing A round shareholders IDG Capital, New Alliance Ca

  • Cancel
    Date：2021-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=831

    On February 24, 2021, YS Biopharma announced the closing of over $130 million in its Series B financing. This round of investment was jointly led by Oceanpine and OrbiMed. Following the Series B financing, the company's institutional investors include Oce

  • Cancel
    Date：2021-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=826

    WuXi Diagnostic rasied $150 million in its Seris B financing, led by Shiyu Investment, Thermo Fisher Scientific, ABC International, Sunland Fund, CCB Sci-Tech Innovation Fund, with continued support from existing shareholder Yunfeng Capital. The funds fro

  • Cancel
    Date：2021-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=832

    As a leading company in radiopharmaceutical targeted diagnosis and treatment, Sinotau Pharmaceutical announced a Series D financing of RMB 320 million. This follows the RMB 280 million raised in Series C financing in July 2020 from investors such as Ruiyi

  • Cancel
    Date：2021-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=519

    Guangzhou Weiyuan (Vision Medicals) Gene Technology Co., Ltd. (hereinafter referred to as “Vision Medicals” or the “Company”), a leader in the infection precision medicine industry, recently announced the completion of a Series B financing round of several hundred million RMB. This round of financing was led by CDH Investment, with participation from CICC Qichen and existing shareholders, Volcanics Venture and Cash Capital. This round of financing will primarily be used for funding product R&D, establishing a clinical testing network, driving product registration efforts, constructing manufacturing facilities, improving clinical services, and increasing brand marketing. CEC Capital Group served as the exclusive financial advisor of Vision Medicals in this transaction.

  • Cancel
    Date：2021-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=828

    Nubo Med, a leading provider of Internet of Things (IoT)-based integrated smart hospital software and hardware solutions, announced today the closing of a Series B financing round, raising several hundred of million RMB. The round was led by SAIF Partners